יחס מחיר להכנסות חזויות Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals (KPRX) is attracting leading ophthalmologists to develop treatments for rare eye pathologies. The expected P/S dynamics on GURU.Markets confirm this status, with the parameter reaching 357.40. While the current revenue deficit and capital burn result in negative earnings, the strategy to scale retina testing is aimed at securing commercial B2B partnerships as quickly as possible.

The forward P/S ratio compares the current market value of Kiora Pharmaceuticals (KPRX) with expected future sales volume, allowing for an assessment of capitalization efficiency relative to prospective cash flows. Analyzing the company's forward P/S helps determine the asset's margin of safety, which is particularly relevant for the non-cyclical ophthalmology sector, where business value depends on the success of clinical trials and patent protection rather than macroeconomics.